2-(pyridin-3-ylsulfanyl)ethanol

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-(pyridin-3-ylsulfanyl)ethanol
• 英文别名: 3-(2-hydroxyethylthio)pyridine；2-Pyridin-3-ylsulfanylethanol
• 化学式: C₇H₉NOS
• 分子量: 155.221
• InChiKey: KANNNRITYPGDNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  58.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(pyridin-3-ylsulfanyl)ethanol 、 ethane,iodozinc(1+) 在 bis-triphenylphosphine-palladium(II) chloride 、 三氟化硼乙醚 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 以49%的产率得到3-乙基吡啶
  参考文献：
  名称：

  Lewis Acid-Promoted Oxidative Addition of Thioimidates to Pd(0)

  摘要：

  The isomeric S-methyldihydropyrrins 9-Z and 9-E exhibit markedly different behavior in Pd(O)catalyzed cross-coupling reactions. Thioimidates 9-Z are readily converted to imines 10-Z employing Pd(0)/AlkZnI. Under identical conditions 9-E are inert. Oxidative addition to Pd(O) requires activation by Zn or other Lewis acids, which is sterically unfavorable with 9-E. Analogous results were obtained with the related thioimidates 11-E,Z as well as with methylthiopyridines 19alpha-gamma. In the case of both 11 and 19 oxidative addition to Pd(O) was greatly facilitated in the presence of BF3.Et2O. The importance of Lewis acid activation to Pd(O) oxidative addition in such substrates appears to be a general phenomenon not previously recognized.

  DOI：

  10.1021/jo026510o
• 作为产物：
  描述：

  吡啶-3-硫醇 、 2-氯乙醇 在 sodium hydride 作用下， 以 水 为溶剂， 反应 1.0h， 生成 2-(pyridin-3-ylsulfanyl)ethanol
  参考文献：
  名称：

  THIAZOLIDINONE COMPOUNDS AND USE THEREOF

  摘要：

  一种含有化合物（I）的药物组合物，用于治疗与阿片受体相关的疾病。还公开了一种使用这种化合物治疗阿片受体相关疾病的方法。进一步公开了两组式（I）的噻唑烷酮化合物：（i）每种化合物的对映体过量大于90%；（ii）每种化合物被氘取代。

  公开号：

  US20170253569A1

文献信息

• New cephem compounds, processes for their preparation, pharmaceutical compositions containing them and intermediate products for their preparation
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0074653A2

  公开（公告）日：1983-03-23

  New cephem cumpounds of the formula: wherein R' is ammo or a protected amino group. R2 is lower aliphatic hydrocarbon group which may be substituted with suitable substituent(s), cylclopower)lalkyl or cyclo(lower)alkenyl; R3 defines certain subsituents, R4 is hydrogen or lower alkyl, and pharmaceutically acceptable salts thereof, processes for their preparation, and a pharmaceutrcal antibacterial composition comprising the above compound in associationwith a pharmaceutically acceptable substantially carrier or excipient.The Invention refers also to compounds of the formula

  式中的新头孢化合物： 式中 R' 是氨基或受保护的氨基。 R2 是可被适当取代基取代的低级脂肪烃基、环烷基或环（低级）烯基； R3 定义某些亚基、 R4 是氢或低级烷基，及其药学上可接受的盐、制备工艺，以及由上述化合物与药学上可接受的基本载体或赋形剂组成的药用抗菌组合物。
• Process for preparing intermediate products and their use for preparing cephem compounds
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0231475A1

  公开（公告）日：1987-08-12

  A process for preparing a compound of the formula : wherein R2 is lower aliphatic hydrocarbon group which may be substituted with suitable substituent(s), cyclo(lower)alkyl or cyclo(lower)alkenyl; or a salt thereof, which comprises reacting a compound of the formula : wherein R2 is as defined above and Y is halogen, or a salt thereof, with a salt of HSCN. The obtained compounds are intermediates which can be used for preparing cephem compounds.

  一种制备式中 R2 为可被适当取代基取代的低级脂族烃基、环（低）烷基或环（低）烯基；或其盐的化合物的工艺，包括将式中 R2 如上定义且 Y 为卤素的化合物或其盐与 HSCN 的盐反应。 得到的化合物为中间体，可用于制备 cephem 化合物。
• VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0620003A1

  公开（公告）日：1994-10-19

  A benzazepine compound represented by formulae (I) or (II) or a salt thereof, and a vasopressin antagonist or an oxytocin antagonist containing the above compound as the active ingredient.

  由式（I）或（II）代表的苯并氮杂卓化合物或其盐，以及含有上述化合物作为活性成分的血管加压素拮抗剂或催产素拮抗剂。
• Vasopressin antagonist and oxytocin antagonist
  申请人：Otsuka Pharmaceutical Company, Limited

  公开号：EP1902717A2

  公开（公告）日：2008-03-26

  An object of the present invention is to provide a vasopressin antagonist and oxytocin antagonist. The vasopressing antagonist and oxytocin antagonist according to the present invention contain, as the active ingredient, a benzoheterocyclic compound represented by the general formula (1): (wherein R1, R2, R3, R4, R5 and the carbon-carbon bond between 4- and 5-positions in the benzoazepine skeleton are the same as defined in Claims 1 and 2) or salt thereof.

  本发明的目的是提供一种血管加压素拮抗剂和催产素拮抗剂。 根据本发明，血管加压素拮抗剂和催产素拮抗剂含有通式（1）所代表的苯并杂环化合物作为活性成分： (其中 R1、R2、R3、R4、R5 和苯并氮杂卓骨架中 4 位和 5 位之间的碳-碳键与权利要求 1 和 2 中定义的相同）或其盐。
• Thiazolidinone compounds and use thereof
  申请人：National Health Research Institutes

  公开号：US10544113B2

  公开（公告）日：2020-01-28

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

  一种含有用于治疗阿片受体相关疾病的式 (I) 化合物的药物组合物。还公开了一种使用此类化合物治疗阿片受体相关疾病的方法。进一步公开了两组式(I)的噻唑烷酮化合物：(i)对映体过量大于 90%的化合物和(ii)各自被氘取代的化合物。